The Florey Institute has released new research that evaluates a new diagnostic blood test for Alzheimer’s and found it is a reliable measure of the disease’s presence and stage.
Plasma pTau217 blood tests have already been shown to accurately detect Alzheimer’s disease but aren’t yet available in a clinical setting.
In research published in eBioMedicine, Florey researchers assessed the test’s performance on the Lumipulse-G® platform which is already in widespread clinical use globally, though is not yet approved for pTau217 tests.
Lumipulse-G® Plasma pTau217 belongs to Japanese diagnostic company Fujirebio, which expects it to be the first commercially-available blood-based in-vitro diagnostic for patients being assessed for Alzheimer’s disease in the US.
The study’s senior author Professor Christopher Rowe – clinical lead of The Florey’s Dementia Mission, and Director of Molecular Imaging Research at Austin Health – said the test proved ‘highly reliable’ in the Lumipulse equipment.
“We compared patients’ blood test results with a PET scan and found that plasma pTau217 not only confirms whether somebody has Alzheimer’s disease, but whether they are at intermediate or advanced stage versus earlier stages,” Professor Rowe said.
Co-first author Azadeh Feizpour said: “With a new generation of drugs emerging to treat Alzheimer’s disease, detecting a person’s stage of disease is going to be important.”
The results were based on patient samples and PET scans provided to the Australian Imaging, Biomarkers and Lifestyle study of ageing (AIBL) and the Australian Dementia Network (ADNeT).
The findings mean that patients are one step closer to a widely available, low-cost test for earlier and accurate diagnosis of Alzheimer’s disease at a time when treatments for early Alzheimer’s Disease are emerging.
